{"denoms":[{"counts":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"56"}],"units":"Participants"}],"groups":[{"description":"Patients with advanced uterine carcinoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Carcinoma"},{"description":"Patients with advanced uterine carcinosarcoma receive 400 mg oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"BG001","title":"Carcinosarcoma"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"44","upperLimit":"83","value":"64"},{"groupId":"BG001","lowerLimit":"40","upperLimit":"87","value":"64"},{"groupId":"BG002","lowerLimit":"40","upperLimit":"87","value":"64"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Customized","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"56"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"39"}]}],"title":"Non-Hispanic white"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"}]}],"title":"Hispanic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}],"title":"African-American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"}]}],"title":"Asian"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"12"}]}],"title":"Adenocarcinoma (unspecified)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"}]}],"title":"Serous"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Clear cell"},{"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"24"}]}],"title":"Endometrioid"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"16"}]}],"title":"Carcinosarcoma"}],"paramType":"NUMBER","title":"Histology","unitOfMeasure":"participants"}]}